Gohibic (Vilobelimab)

Gohibic (vilobelimab) is investigated for use in diseases where complement‑mediated inflammation contributes to pathology.

• Severe COVID‑19 pneumonia requiring hospitalization, where excessive C5a activity is implicated.
• Acute respiratory distress syndrome (ARDS) associated with hyperinflammatory responses.
• Certain autoimmune disorders characterized by complement activation, such as systemic lupus erythematosus flares.
• Experimental treatment protocols for cytokine release syndrome in oncology patients.
• Investigational use in transplant‑related inflammatory complications.

The safety profile of Gohibic reflects the pharmacology of complement inhibition and includes both frequent mild reactions and less common serious events.

Common

• Infusion‑related reactions such as flushing, chills, or mild fever.
• Headache or dizziness during or shortly after administration.
• Nausea or mild gastrointestinal discomfort.
• Transient elevation of liver enzymes.

Serious

• Severe hypersensitivity or anaphylaxis.
• Increased susceptibility to bacterial infections, particularly encapsulated organisms.
• Thrombotic microangiopathy or clotting abnormalities.

Before initiating Gohibic, clinicians should evaluate patient history and monitor for conditions that could be worsened by complement blockade.

• Assess for active or recent serious infections; defer treatment if uncontrolled.
• Screen for known hypersensitivity to vilobelimab or any excipients in the formulation.
• Evaluate vaccination status, especially against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b.
• Monitor complete blood count and liver function tests during therapy.
• Use caution in patients with a history of thrombotic events or coagulopathy.
• Consider pregnancy and lactation status; limited data are available.

Vilobelimab may interact with other agents that affect immune function or complement pathways.

Avoid

• Concurrent use of other complement inhibitors (e.g., eculizumab) due to overlapping mechanisms.
• Live bacterial vaccines administered during treatment, which may have reduced efficacy.

Use with caution

• Immunosuppressive drugs such as high‑dose corticosteroids or cytotoxic agents; infection risk may increase.
• Anticoagulants, because of reported clotting abnormalities in rare cases.
• Antibiotics targeting encapsulated bacteria; monitor for breakthrough infections.
• Concomitant biologics that modulate cytokine activity; assess cumulative immunomodulation.